Chiesi Advances Carbon Minimal Inhaler Program as EMA Validates HFA-152a Propellant Submissions for Fostair and Trimbow
Chiesi Group announced Thursday September 3, 2026 that the European Medicines Agency validated regulatory submissions for the Single Inhaler Triple Therapy (Trimbow, beclomethasone dipropionate / formoterol fumarate / glycopyrronium bromide) and the ICS/LABA combination (Fostair, beclomethasone dipropionate / formoterol fumarate) reformulated with HFA-152a — a next-generation non-PFAS propellant with low global warming potential. The reformulated pressurized metered-dose inhalers are designed to reduce the carbon footprint of the products by up to 90% versus the current HFA-134a formulations. In July 2026, the UK Medicines and Healthcare products Regulatory Agency approved Chiesi's beclomethasone pMDI with HFA-152a as the first UK approval of the next-generation propellant. The Chiesi Carbon Minimal Inhaler program is the pharmaceutical industry's leading environmental sustainability initiative and provides a template for GSK, AstraZeneca, and Teva reformulation of Ellipta/Advair/Symbicort/ProAir portfolios that account for approximately 3% of the UK NHS carbon footprint.